4 active not recruiting, 3 completed, 2 not yet recruiting, 2 recruiting. 11 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Active not recruiting 4, Completed 3, Not yet recruiting 2, Recruiting 2 |
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Overweight , Obesity: new trials by email Literature Review of Overweight , Obesity trials Research Report on Overweight , Obesity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity ecnoglutide tablet, placebo with matching dosage - Overweight , Obesity, Weight Management | Phase 2 | Not yet recruiting | Hangzhou Sciwind Biosciences Co., Ltd. | 180 | 2026-11-10 | 2026-11-10 |
| Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity. Semaglutide, Placebo - Type 1 Diabetes, Overweight , Obesity | Phase 2 / Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 40 | 2026-10-13 | 2026-10-23 |
| Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss ALV-100, Placebo - Overweight , Obesity, Adults | Phase 2 | Recruiting | Alveus Therapeutics, Inc. | 220 | 2026-08-10 | 2026-10-26 |
| A Study of SRSD384 in Overweight or Obese Participants SRSD384 injection, Placebo - Overweight , Obesity | Phase 1 / Phase 2 | Not yet recruiting | Sirius Therapeutics Co., Ltd. | 78 | 2026-06-01 | 2026-06-05 |
| Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity MWN109 1, MWN109 2 - Overweight , Obesity | Phase 2 | Active not recruiting | Shanghai Minwei Biotechnology Co., Ltd | 71 | 2026-03-02 | 2026-09-04 |
| Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity MWN109 1, MWN109 2, MWN109 3 - Overweight , Obesity | Phase 2 | Completed | Shanghai Minwei Biotechnology Co., Ltd | 255 | 2026-01-05 | 2026-08-28 |
| Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight MWN109 1, MWN109 2, MWN109 3 - Overweight , Obesity | Phase 2 | Active not recruiting | Shanghai Minwei Biotechnology Co., Ltd | 125 | 2025-12-26 | 2026-08-28 |
| Efficacy and Safety of ZT006 in Overweight and Obese Participants ZT006, Placebo of ZT006 - Overweight , Obesity | Phase 2 | Active not recruiting | Beijing QL Biopharmaceutical Co.,Ltd | 184 | 2025-12-12 | 2026-06-12 |
| Phase 2 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity MWN105 1, MWN105 2, MWN105 3 - Overweight , Obesity | Phase 2 | Completed | Shanghai Minwei Biotechnology Co., Ltd | 120 | 2025-09-03 | 2026-09-04 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity MWN109 1, MWN109 2, MWN109 3 - Overweight , Obesity | Phase 2 | Completed | Shanghai Minwei Biotechnology Co., Ltd | 120 | 2025-08-23 | 2026-08-28 |
| Study on the Efficacy of Probiotics in the Treatment of Childhood Obesity and Their Effects on Gut Microbiota Probiotic, Placebo - Overweight , Obesity | Phase 2 | Active not recruiting | Min-Tze LIONG | 60 | 2023-12-01 | 2026-03-04 |
Obesity (11) · Overweight (11) · Diabetes Mellitus, Type 1 (1)
Body Weight (11) · Nutrition Disorders (11) · Nutritional and Metabolic Diseases (11) · Overnutrition (11) · Pathological Conditions, Signs and Symptoms (11) · Signs and Symptoms (11) · Autoimmune Diseases (1) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Immune System Diseases (1) · Metabolic Diseases (1)
Probiotics (1) · Saline Solution (1) · semaglutide (1)
Shanghai Minwei Biotechnology Co., Ltd (5) · Alveus Therapeutics, Inc. (1) · Beijing QL Biopharmaceutical Co.,Ltd (1) · Hangzhou Sciwind Biosciences Co., Ltd. (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Min-Tze LIONG (1) · Sirius Therapeutics Co., Ltd. (1)
China (8) · Australia (1) · Canada (1) · Malaysia (1) · United States (1)
Aihua Zhang, MD. (1) · Hongwei Jiang (1) · Linong Ji, MD (1) · Melissa-Rosina Pasqua, MD, PhD (1)